



Cite this: *RSC Adv.*, 2017, 7, 22360

Application of quinazoline and pyrido[3,2-*d*]pyrimidine templates to design multi-targeting agents in Alzheimer's disease†

Tarek Mohamed,^{ab} Mandeep K. Mann^a and Praveen P. N. Rao *^a

A quinazoline and pyrido[3,2-*d*]pyrimidine based compound library was designed, synthesized and evaluated as multi-targeting agents aimed at Alzheimer's disease (AD). The SAR studies identified compound **8h** (8-chloro-*N*²-isopropyl-*N*⁴-phenethylquinazoline-2,4-diamine) as a potent inhibitor of Aβ40 aggregation (IC₅₀ = 900 nM) which was 3.6-fold more potent compared to the reference agent curcumin (Aβ40 IC₅₀ = 3.3 μM). It also exhibited dual ChE inhibition (AChE IC₅₀ = 8.6 μM; BuChE IC₅₀ = 2.6 μM). Compound **9h** (8-chloro-*N*⁴-(3,4-dimethoxyphenethyl)-*N*²-isopropylquinazoline-2,4-diamine) was identified as the most potent Aβ42 aggregation inhibitor (IC₅₀ ~ 1.5 μM). Transmission electron microscopy (TEM) imaging demonstrates their anti-Aβ40/Aβ42 aggregation properties. Compound **8e** was identified as a potent BuChE inhibitor (BuChE IC₅₀ = 100 nM) which was 36-fold more potent compared to donepezil (BuChE IC₅₀ = 3.6 μM). The pyrido[3,2-*d*]pyrimidine bioisostere **10b** (*N*²-isopropyl-*N*⁴-phenethylpyrido[3,2-*d*]pyrimidine-2,4-diamine) exhibited good anti-Aβ activity (Aβ40 IC₅₀ = 1.1 μM), dual ChE inhibition and iron-chelating properties (23.6% chelation at 50 μM). These investigations demonstrate the usefulness of either a quinazoline or a pyrido[3,2-*d*]pyrimidine based ring scaffold in the design of multi-targeting agents to treat AD.

Received 9th March 2017
Accepted 17th April 2017

DOI: 10.1039/c7ra02889j

rsc.li/rsc-advances

1 Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder with no cure in sight. It is anticipated that with an aging population and increasing lifespan, the social and economic burden is going to multiply in the years to come. Current AD research indicates that many factors are involved in its pathophysiology. Due to the ever-growing complexity of AD, it is no surprise that the shift toward multi-targeting small molecule candidates which can counter the various facets of the disease, as the next generation AD treatments is increasing.¹⁻³ While current pharmacotherapy options rely on cholinesterase inhibitors (donepezil, rivastigmine and galantamine) that reduce the degradation of the neurotransmitter acetylcholine (ACh) and an *N*-methyl-*D*-aspartate antagonist (memantine), these were not designed as multi-targeting agents and provide only symptomatic relief.^{4,5} The role of beta-amyloid (Aβ) which tends to form neurotoxic aggregates, cholinesterases (ChE) that degrade ACh which facilitates neurotransmission and oxidative stress

including metal-induced neurotoxicity in AD disease pathophysiology, highlights the need to design and develop novel therapies to target multiple pathways.⁶⁻¹⁰

As part of our research program aimed at designing multi-targeting small molecules, we have investigated the development of novel agents including quinazolines that exhibit Aβ aggregation inhibition, dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition and possess radical scavenging activity.^{11,12} In this regard, dual inhibition of both AChE and BuChE is known to be beneficial as BuChE can process ACh in advance stages of AD.¹³ Building on our recent efforts on multi-targeting small molecules, herein we present the structure-activity relationship (SAR) studies of substituted quinazolines and its bioisostere, pyrido[3,2-*d*]pyrimidine ring template (Fig. 1). Several compounds from this series exhibited





Fig. 1 SAR studies of quinazoline and pyrido[3,2-*d*]pyrimidines as multi-targeting anti-AD agents.

^aSchool of Pharmacy, Health Sciences Campus, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1. E-mail: praopera@uwaterloo.ca; Tel: +1-519-888-4567 ext. 21317

^bDepartment of Chemistry and School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada N2L 3G1

† Electronic supplementary information (ESI) available: Includes ¹H NMR spectra. See DOI: 10.1039/c7ra02889j





Scheme 1 Reagents and conditions: (a) urea, pressure vial, 150–155 °C, 2 h; (b) toluene, *N,N*-diethylaniline, POCl₃, 0–105 °C, reflux, 14–16 h.


desirable multi-targeting ability including dual Aβ/ChE inhibition and iron chelation properties. The road toward this library of 32 derivatives (**8–15**) started by first reacting the substituted-chloro-2-aminobenzoic or picolinic acids (**1a–d**, Scheme 1) with urea to afford the quinazoline or pyrido[3,2-*d*]pyrimidine ring template (**2a–d**), followed by 2,4-dichlorination with POCl₃ to obtain 2,4,6-, 2,4,7- or 2,4,8-trichloroquinazolines (**3a–c**) or 2,4-dichloropyrido[3,2-*d*]pyrimidine (**3d**) respectively (65–80% yield, Scheme 1).¹²

The *N*⁴-substituted dichloroquinazolines (**4a–c** and **5a–c**) or *N*⁴-substituted-2-chloropyrido[3,2-*d*]pyrimidine (**6a** and **7a**) intermediates were obtained in moderate to good yields (~75–90%) by coupling **3a–d** with phenethylamine or 3,4-dimethoxyphenethylamine in the presence of *N,N*-diisopropylethylamine (DIPEA) under reflux for 4 hours (Scheme 2). Displacement of the C2 chlorine in **4a–c**, **5a–c**, **6a** and **7a** was readily achieved by heating with respective amines (*n*-propylamine, isopropylamine, cyclopropylamine or *N,N*-dimethylamine) with 1,4-dioxane in the presence of DIPEA, in a pressure vial for 2 h to afford the quinazoline (Qnz) and pyrido[3,2-*d*]pyrimidine (Ppd) based compound library **8a–i**, **9a–i**, **10a–c**, **11a–c**, **12a–c**, **13a–c**, **14a** and **15a** with yields ranging from 68–78% (Scheme 1). The synthesized quinazoline derivatives were evaluated for their ability to modulate the aggregation kinetics of Aβ₄₀ and Aβ₄₂ using the thioflavin T (ThT) fluorescence assay.^{12,14} Their cholinesterase (*h*AChE/*h*BuChE) inhibition activity was determined using the Ellman's protocol.^{12,15} We identified few chloroquinazoline and pyrido[3,2-*d*]pyrimidines that exhibited excellent Aβ aggregation inhibition, dual ChE inhibition and iron-chelation properties thereby demonstrating multi-targeting ability.

2 Results and discussion

2.1 Inhibition of Aβ aggregation

The results of the SAR investigation on the anti-Aβ aggregation properties of chloroquinazolines and pyrido[3,2-*d*]pyrimidines is shown in Table 1. Examining the SAR of C4 phenethylamine-based chloroquinazolines (**8a–i**), shows that chlorine placement on the quinazoline ring had an effect on anti-Aβ activity with the 8-Cl placement exhibiting superior Aβ aggregation inhibition. The activity order was 8-Cl > 7-Cl > 6-Cl with respect to both Aβ₄₀/Aβ₄₂ inhibition. While **8a–c** was ineffective toward Aβ₄₂, others in the group showed inhibition ranging from ~3.9–12 μM, with **8h** being the most potent Aβ₄₂ inhibitor. Significant Aβ₄₀ aggregation inhibition was observed with compounds **8g–i** (~900 nM to 3.7 μM), with **8h** (8-Cl, C2 *i*-Pr) being the most potent inhibitor (Aβ₄₀ IC₅₀ = 900 nM) and was 3.6-fold more potent compared to the reference agent curcumin (Aβ₄₀ IC₅₀ = 3.3 μM, Table 1). The addition of a C4 3,4-dimethoxyphenethylamine substituent in compounds (**9a–i**) generally provided dual inhibition of both Aβ₄₀ and Aβ₄₂ aggregation except for the 7-chloro derivative **9e** (Table 1). Compound **9h** (8-chloro, C2 *i*-Pr) was identified as a good inhibitor of both Aβ₄₀ and Aβ₄₂ (Aβ₄₀ IC₅₀ ~ 4.0 μM; Aβ₄₂ IC₅₀ ~ 1.5 μM). Significantly, it was ~6.6-fold and 10-fold more potent toward Aβ₄₂ compared to reference agents resveratrol (Aβ₄₂ IC₅₀ = 15.3) and curcumin (Aβ₄₂ IC₅₀ = 9.9 μM). Replacing the quinazoline ring template with a pyrido[3,2-*d*]pyrimidine bioisostere was generally ineffective. In this group of compounds, the C4 phenethylamine derivatives **10a–c** were better than the corresponding C4 3,4-dimethoxyphenethylamine derivatives **11a–c** with compound **10b** identified as the most potent Aβ₄₀ aggregation



Scheme 2 Reagents and conditions: (a) phenethylamine or 3,4-dimethoxyphenethylamine, DIPEA, ethanol, reflux, 80–85 °C, 4 h; (b) alkylamine, DIPEA, 1,4-dioxane, 150–155 °C, pressure vial, 2 h.



Table 1 Amyloid- β (A β 40/A β 42) inhibition activity of quinazolines (**8**, **9**, **12** and **13**) and pyrido[3,2-*d*]pyrimidines (**10**, **11**, **14** and **15**)

Compd	R ¹	Chloride substitution	IC ₅₀ ^{a,b} (μ M)	
			A β 40	A β 42
8a	<i>n</i> -Pr	C6	>25	>25
8b	<i>i</i> -Pr	C6	8.6 \pm 0.7	>25
8c	<i>c</i> -Pr	C6	8.7 \pm 0.9	>25
8d	<i>n</i> -Pr	C7	6.9 \pm 1.4	4.6 \pm 0.9
8e	<i>i</i> -Pr	C7	6.1 \pm 1.3	7.2 \pm 1.6
8f	<i>c</i> -Pr	C7	4.8 \pm 1.0	11.7 \pm 2.0
8g	<i>n</i> -Pr	C8	3.7 \pm 0.5	6.5 \pm 0.4
8h	<i>i</i> -Pr	C8	0.9 \pm 0.1	3.9 \pm 0.5
8i	<i>c</i> -Pr	C8	1.3 \pm 0.2	6.8 \pm 1.3
9a	<i>n</i> -Pr	C6	4.9 \pm 0.5	10.7 \pm 1.1
9b	<i>i</i> -Pr	C6	5.8 \pm 0.7	7.7 \pm 0.8
9c	<i>c</i> -Pr	C6	8.9 \pm 0.9	9.8 \pm 0.8
9d	<i>n</i> -Pr	C7	3.1 \pm 0.3	12.4 \pm 1.1
9e	<i>i</i> -Pr	C7	10.6 \pm 0.9	>25
9f	<i>c</i> -Pr	C7	5.2 \pm 0.6	22.5 \pm 1.9
9g	<i>n</i> -Pr	C8	4.9 \pm 0.5	2.3 \pm 0.3
9h	<i>i</i> -Pr	C8	4.0 \pm 0.4	1.5 \pm 0.2
9i	<i>c</i> -Pr	C8	4.6 \pm 0.5	2.2 \pm 0.2
10a	<i>n</i> -Pr	—	NA	13.7 \pm 2.0
10b	<i>i</i> -Pr	—	1.1 \pm 0.1	>25
10c	<i>c</i> -Pr	—	6.8 \pm 1.0	11.5 \pm 1.5
11a	<i>n</i> -Pr	—	NA	>25
11b	<i>i</i> -Pr	—	NA	>25
11c	<i>c</i> -Pr	—	>25	>25
12a	—	C6	6.5 \pm 0.9	>25
12b	—	C7	5.1 \pm 1.7	>25
12c	—	C8	1.9 \pm 0.3	>5.8 \pm 0.7
13a	—	C6	2.5 \pm 0.3	5.6 \pm 0.7
13b	—	C7	4.3 \pm 0.4	9.4 \pm 0.9
13c	—	C8	2.3 \pm 0.2	1.8 \pm 0.3
14a	—	—	NA	12.7 \pm 2.0
15a	—	—	>25	>25
Resveratrol	—	—	1.1 \pm 0.1	15.3 \pm 1.9
Curcumin	—	—	3.3 \pm 0.4	9.9 \pm 0.4

^a IC₅₀ values were calculated using the ThT-based fluorescence spectroscopy assay (excitation = 440 nm, emission = 490 nm).

^b Values are mean of triplicate readings for three independent experiments. NA = not active.

inhibitor (IC₅₀ \sim 1.1 μ M). In the next step, the impact of a tertiary dimethylamine moiety at the C2-position was investigated. The presence of a C4 phenethylamine, increased potency toward A β 40 **12a–c**; 6-Cl < 7-Cl < 8-Cl while only **12c** was active toward A β 42. On the other hand, with a 3,4-dimethoxyphenethylamine at the C4 position, potency toward A β 40 ranged from \sim 2–4 μ M with chlorine placement at C6 being equipotent to C8 placement. The A β 42 aggregation inhibitory potency increased from 7-Cl (**13b**, IC₅₀ \sim 9.4 μ M) to 6-Cl (**13a**, IC₅₀ \sim 5.6 μ M) to 8-Cl (**13c**, IC₅₀ \sim 1.8 μ M). Combining the C2 dimethylamine group with a C4 phenethylamine or 3,4-dimethoxyphenethylamine on a pyrido[3,2-*d*]pyrimidine scaffold resulted in either weak or no inhibition of A β aggregation (compounds **14a** and **15a**, Table 1). With respect to the A β aggregation inhibition SAR, \sim 22% of the derivatives screened surpassed the activity level of curcumin toward A β 40, while \sim 44% surpassed the activity level of curcumin toward A β 42.

Derivative **8h** (8-chloro-*N*²-isopropyl-*N*⁴-phenethylquinazoline-2,4-diamine) was the most potent A β 40 aggregation inhibitor (IC₅₀ \sim 900 nM), while **9h** (8-chloro-*N*⁴-(3,4-dimethoxyphenethyl)-*N*²-isopropylquinazoline-2,4-diamine) was the most potent A β 42 aggregation inhibitor (IC₅₀ \sim 1.5 μ M).

The ThT-based A β 40 aggregation kinetics data in the presence of the most active inhibitors (**8h** and **10b** for A β 40) is shown in Fig. 2. This reveals that, their modes of aggregation inhibition do differ from one another. As seen in Fig. 2 (panel A), **8h** was exhibiting a concentration-dependent reduction in the aggregation with complete inhibition of A β 40 aggregation seen at 25 μ M. On the other hand, **10b** (Fig. 2, panel C) was also exhibiting a concentration-dependent reduction in aggregation. In addition, unlike compound **8h**, it was able to delay the onset of aggregation by delaying the lag phase further. Investigating the A β morphology by TEM imaging further confirms the ability of both compounds **8h** and **10b** to prevent A β aggregation (Fig. 2). Analysis of the A β 42 aggregation kinetics in the presence of the most active inhibitors (**9h** and **13c** for A β 42, Fig. 2) revealed similar observations. Both derivatives, which were nearly equipotent against A β 42 aggregation, shared similar modes of action. As seen in Fig. 2 (panel B), **9h** was able to reduce the overall load of A β 42 fibril formation in a concentration dependent manner with almost complete inhibition seen at 25 μ M. A similar trend was seen with **13c** (Fig. 2, panel D). Furthermore, TEM morphology studies corroborate aggregation kinetics data observed (Fig. 2).

The molecular docking study of best two A β 40 aggregation inhibitors, **8h** and **10b**, in the A β dimer model (Fig. 3, panel A) derived from the solution structure of A β fibrils¹⁶ (pdb id:2LMN) indicated that both the 8-chloroquinazoline and the pyrido[3,2]pyrimidine templates were oriented between C- and N-terminal region whereas the C4-phenethylamine substituent was closer to the turn region Asp23-Gly29 (distance \sim 6–8 Å). Hydrophobic interactions were the dominating force involved. In the pyrido[3,2-*d*]pyrimidine compound **10b**, the presence of an additional ring nitrogen (N5) led to a hydrogen bonding contact with the amide backbone of Val24 (distance \sim 3 Å). In the fibril model, Fig. 3, panel B, both **8h** and **10b** had similar binding modes where the C4-phenethylamine group was oriented toward the center region of the fibril core (Ile32-Met35, distance \sim 5–8 Å). Both core templates were undergoing hydrophobic interactions with Ile31-Val38 (distance \sim 5–8 Å) at the C-terminal end. These studies support the ability of **8h** and **10b** to reduce fibril aggregation.

2.2 Inhibition of cholinesterases

With respect to cholinesterase inhibition, the SAR data is shown in Table 2. While examining the first cluster of C4 phenethylamine-based chloroquinazolines (**8a–i**), it became evident that chlorine placement at either C6, C7 or C8 was able to modulate the ChE inhibitory activity with 7-Cl exhibiting better ChE inhibition. The ChE inhibition can be ranked as 7-Cl > 6-Cl > 8-Cl with respect to both ChEs. Most noteworthy was the outcome from **8e** (AChE IC₅₀ \sim 6.6 μ M, BuChE IC₅₀ \sim 100 nM), which was the most potent AChE inhibitor in this group, and






Fig. 2 A β 40/A β 42 (5 μ M) aggregation kinetics study with or without 1, 5 or 25 μ M of 8h (panel A), 9h (panel B), 10b (panel C) or 13c (panel D) along with corresponding TEM morphology in the presence of 25 μ M of 8h, 9h, 10b or 13c. Aggregation kinetics were monitored by ThT-fluorescence spectroscopy (excitation = 440 nm, emission = 490 nm) for 24 h at 37 $^{\circ}$ C in phosphate buffer at pH 7.4. TEM image scale: white bars represent 500 nm.




Fig. 3 A β molecular docking studies. Binding modes of the quinazoline compound **8h** (red) and pyrido[3,2-*d*]pyrimidine compound **10b** (green) in A β -dimer model (panel A) and A β -fibril model (panel B). Hydrogen atoms were removed for clarity.

was the most potent BuChE inhibitor overall (about 36-fold more potent compared to donepezil, $IC_{50} = 3.60 \mu\text{M}$). The addition of the 3,4-dimethoxyphenethyl substituent in the second cluster of derivatives (**9a–i**) exhibited similar AChE inhibition range as per compounds **8a–i**. However, it was detrimental for BuChE inhibition, although one key derivative stood out from the pack (**9e**, BuChE $IC_{50} \sim 4 \mu\text{M}$) and was equivalent to donepezil. It is interesting to point out that both compounds **8e** and **9e** that exhibited significant BuChE inhibition possessed a C2 isopropylamine substituent which promoted BuChE inhibition. Replacing the quinazoline

template with a pyrido[3,2-*d*]pyrimidine template (**10a–c** and **11a–c**), led to weak or no inhibitory activity toward BuChE. With respect to AChE inhibition, they were on par with the chloroquinazolines (**8a–i** and **9a–i**) with activity range AChE $IC_{50} \sim 7–8 \mu\text{M}$, Table 2. The incorporation of a *N,N*-dimethylamine at the C2 position was explored to investigate the role of a tertiary amine instead of a secondary amine toward ChE inhibition (**12a–c** and **13a–c**). The chlorine placement played a role as **12b** (7-Cl, BuChE $IC_{50} \sim 1.5 \mu\text{M}$) was ~ 3.6 -fold more potent compared to its 6-chloro isomer (**12a**). In addition, **12b** was more potent compared to compound **13b** (BuChE $IC_{50} > 50 \mu\text{M}$).



Table 2 Cholinesterase inhibition (AChE and BuChE) of quinazolines (8, 9, 12 and 13) and pyrido[3,2-*d*]pyrimidines (10, 11, 14 and 15)

Compd	R ¹	Chloride substitution	IC ₅₀ ^a (μM)	
			<i>h</i> AChE	<i>h</i> BuChE
8a	<i>n</i> -Pr	C6	8.9 ± 0.6	4.8 ± 0.3
8b	<i>i</i> -Pr	C6	8.7 ± 0.5	1.5 ± 0.1
8c	<i>c</i> -Pr	C6	8.7 ± 0.9	9.1 ± 0.7
8d	<i>n</i> -Pr	C7	7.2 ± 0.7	4.4 ± 0.4
8e	<i>i</i> -Pr	C7	6.6 ± 0.6	0.1 ± 0.02
8f	<i>c</i> -Pr	C7	7.3 ± 0.6	3.5 ± 0.4
8g	<i>n</i> -Pr	C8	7.7 ± 0.7	6.0 ± 0.6
8h	<i>i</i> -Pr	C8	8.6 ± 0.9	2.6 ± 0.2
8i	<i>c</i> -Pr	C8	7.6 ± 0.7	10.9 ± 0.9
9a	<i>n</i> -Pr	C6	6.2 ± 0.4	>50
9b	<i>i</i> -Pr	C6	6.8 ± 0.7	20.3 ± 1.5
9c	<i>c</i> -Pr	C6	8.0 ± 0.7	>50
9d	<i>n</i> -Pr	C7	7.2 ± 0.7	>50
9e	<i>i</i> -Pr	C7	7.9 ± 0.8	3.9 ± 0.3
9f	<i>c</i> -Pr	C7	8.7 ± 0.8	>50
9g	<i>n</i> -Pr	C8	6.5 ± 0.5	>50
9h	<i>i</i> -Pr	C8	6.8 ± 0.7	19.3 ± 1.1
9i	<i>c</i> -Pr	C8	6.6 ± 0.7	>50
10a	<i>n</i> -Pr	—	8.1 ± 0.8	30.3 ± 2.8
10b	<i>i</i> -Pr	—	7.8 ± 0.8	29.3 ± 2.0
10c	<i>c</i> -Pr	—	7.6 ± 0.6	>50
11a	<i>n</i> -Pr	—	7.2 ± 0.8	>50
11b	<i>i</i> -Pr	—	7.4 ± 0.7	>50
11c	<i>c</i> -Pr	—	7.2 ± 0.5	>50
12a	—	C6	7.7 ± 0.8	5.4 ± 0.6
12b	—	C7	5.8 ± 0.7	1.5 ± 0.1
12c	—	C8	7.5 ± 0.8	>50
13a	—	C6	7.2 ± 0.7	31.2 ± 3.4
13b	—	C7	13.4 ± 1.1	>50
13c	—	C8	8.1 ± 0.8	>50
14a	—	—	6.8 ± 0.7	>50
15a	—	—	6.7 ± 0.5	>50
Donepezil	—	—	0.03 ± 0.002	3.6 ± 0.4
Galantamine	—	—	2.6 ± 0.6	>50

^a IC₅₀ values were an average ± SD of triplicate readings for two to three independent experiments.

This trend also extended to the AChE profiles, where **12b** (AChE IC₅₀ ~ 5.8 μM) was ~2.3-fold more potent compared to **13b**, it was also ~1.3-fold more potent compared to its 6- and 8-chloro isomers (**12a** and **12c**). These studies show that combining the *N,N*-dimethylamine group at C2 with phenethylamine or 3,4-dimethoxyphenethylamine on a pyrido[3,2-*d*]pyrimidine scaffold resulted in equipotent and selective AChE inhibition (**14a** and **15a**, AChE IC₅₀ ~ 6.7 μM, BuChE IC₅₀ > 50 μM, Table 2). The quinazoline derivative **8e** (7-chloro-*N*²-isopropyl-*N*⁴-phenethylquinazoline-2,4-diamine) was the most potent BuChE inhibitor with an IC₅₀ ~ 100 nM, while **12b** (7-chloro-*N*²,*N*²-dimethyl-*N*⁴-phenethylquinazoline-2,4-diamine) was the most potent AChE inhibitor with an IC₅₀ ~ 5.8 μM.

The binding interaction of quinazoline derivatives was investigated by using the X-ray crystal structures of human AChE (pdb id:1B41) and BuChE (pdb id:1P0I) enzymes.^{17,18} The binding modes of two best quinazoline based AChE inhibitors **9a** and **12b** in *h*AChE (Fig. 4, panel A) revealed quite similar




Fig. 4 Cholinesterase molecular docking studies. Panel (A): Binding modes of **9a** (red) and **12b** (green) in *h*AChE. Panel (B): Binding modes of **8e** (red) and **12b** (green) in *h*BuChE. Hydrogen atoms removed for clarity.

binding interactions, explaining their near-equipotent inhibition of the AChE (IC₅₀ ~ 6 μM). In both derivatives, the 7-chloroquinazoline ring scaffold was stacked parallel against Trp86 (distance ~ 4–6 Å) and the C4-benzylamino groups were extending from the catalytic site toward the peripheral anionic site (PAS), where the 3,4-dimethoxy moiety of compound **9a** was undergoing favorable interactions with Trp286 (distance ~ 3–4 Å). The C6 and C7 chlorine atoms were oriented toward the catalytic triad (distance ~ 6–8 Å), while the C2-alkylamine groups underwent hydrophobic interactions with Trp86 (distance ~ 3–5 Å). The binding orientation of compounds **8e** and **12b** that exhibited superior inhibitory potency toward BuChE was quite different (Fig. 4, panel B). The most potent BuChE inhibitor **8e** underwent three hydrogen-bonding interactions centered around the C2 isopropylamine-NH, the 7-chloroquinazoline-*N*1 with His447 and Ser203 duo (distance ~ 2.5–3.5 Å). The core ring scaffold was also oriented in the catalytic triad, with the C7 chlorine oriented toward the acyl pocket (Leu286-Val288, distance ~ 4–5 Å). The C4-phenethylamine substituent was oriented perpendicular to Trp82 (Fig. 4, panel B). On the other hand, derivative **12b** had its core scaffold and C4-phenethylamine substituent directly interacting with Trp82 (distance ~ 3–4 Å), while the *N,N*-dimethylamine was oriented toward the catalytic triad (distance ~ 4–5 Å) which explains their superior inhibition profile.

2.3 Iron chelation properties

The presence of an additional ring nitrogen in the pyrido[3,2-*d*]pyrimidine class of compounds (**10a–c**, **11a–c**, **14a** and **15a**) provides a chelation center.^{19,20} Due to the role of iron in promoting oxidative stress in AD^{21–23} and its contribution in the formation of neurotoxic Aβ plaques and neurofibrillary tangles (NFTs), we assessed the Fe²⁺-chelation potential of the pyrido[3,2-*d*]pyrimidines (Table 3) in ferrozine based assay. The known iron chelators clioquinol and deferoxamine were used as reference agents. These studies show that, the C4 phenethylamine substituted compounds **10a–c** exhibited better chelation capacity compared to their C4 3,4-



Table 3 Iron (Fe²⁺) chelation studies of pyrido[3,2-*d*]pyrimidines

Compd	R	R ¹	% Fe ²⁺ Chelation ^a
10a	Phenethyl	<i>n</i> -Pr	29.3 ± 4.3
10b	Phenethyl	<i>i</i> -Pr	23.6 ± 4.0
10c	Phenethyl	<i>c</i> -Pr	37.0 ± 5.6
11a	3,4-DiOMe-phenethyl	<i>n</i> -Pr	24.1 ± 3.6
11b	3,4-DiOMe-phenethyl	<i>i</i> -Pr	21.8 ± 3.3
11c	3,4-DiOMe-phenethyl	<i>c</i> -Pr	26.7 ± 4.0
14a	Phenethyl	—	22.9 ± 3.4
15a	3,4-DiOMe-phenethyl	—	23.0 ± 3.0
Clioquinol	—	—	39.0 ± 5.8
Deferoxamine	—	—	86.7 ± 11.0

^a % Fe²⁺ chelation values were an average ± SD of duplicate readings for two independent experiments. The ferrozine absorbance was measured at 562 nm.

dimethoxyphenethyl dimethoxyphenethylamine counterparts **11a–c**, **14a** and **15a** (inactive at 50 μM).

Overall, these pyrido[3,2-*d*]pyrimidine compounds exhibited weak to moderate (22–37% chelation) iron-chelation capacity. Interestingly, the presence of a C2 cyclopropyl substituent provided the best chelation capacity compared to other C2 substituents explored with compound **10c** exhibiting equipotent iron-chelation capability (37% chelation at 50 μM) compared to the reference agent clioquinol (39% inhibition at 50 μM, Table 3). More significantly, the corresponding quinazoline class of compounds did not exhibit any iron-chelation capacity highlighting the requirement of a pyrido[3,2-*d*]pyrimidine ring scaffold to display iron-chelation properties.

3 Conclusions

In summary, we synthesized and optimized the structure of quinazoline based ring scaffold as multi-targeting agents aimed at the amyloid, cholinergic, and oxidative stress pathways of AD pathophysiology. A number of agents synthesized exhibited dual Aβ, ChE inhibition and iron-chelation capacity. The SAR acquired shows that compound **8h** was the most potent Aβ40 aggregation inhibitor (IC₅₀ = 900 nM) and compound **8e** provided dual Aβ (IC₅₀ Aβ40 = 6.1 μM; Aβ42 IC₅₀ = 7.2 μM) and ChE inhibition (IC₅₀ AChE = 6.6 μM; BuChE IC₅₀ = 100 nM). The presence of a pyrido[3,2-*d*]pyrimidine bioisostere instead of a quinazoline was essential to exhibit iron-chelation properties (22–37% chelation) with compounds **10b** and **10c** exhibiting multi-targeting activity toward Aβ, ChE and iron-chelation properties. The data presented herein highlights the dual anti-Aβ40/β42 aggregation, ChE inhibition, and metal-chelation capabilities of quinazoline and pyrido[3,2-*d*]pyrimidine class of compounds as multi-targeting agents to treat AD.

4 Materials and methods

4.1 General information

All chemicals and reagents used were purchased from either Sigma-Aldrich, USA or Alfa Aesar, USA and was used without

further purification. Melting points were determined using a Fisher-Johns melting point apparatus and are uncorrected. ¹H NMR (300 MHz) and ¹³C NMR spectra (100 MHz) were recorded on a Bruker Avance NMR spectrometer in DMSO-*d*₆. Coupling constants (*J* values) were recorded in hertz (Hz) and the following abbreviations were used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. Carbon multiplicities (C, CH, CH₂ and CH₃) were assigned by DEPT 90/135 experiments. Low-resolution mass spectra (LRMS) was obtained using an Agilent 6100 series single quad LCMS whereas high-resolution mass spectra (HRMS) were recorded on a Thermo Scientific Q Exactive™ mass spectrometer with an ESI source, Department of Chemistry, University of Waterloo. Compound purity was assessed (~95% purity) using an Agilent 6100 series single quad LCMS equipped with an Agilent 1.8 μm Zorbax Eclipse Plus C18 (2.1 × 50 mm) running 50 : 50 water/ACN with 0.1% FA at a flow rate of 0.5 mL min⁻¹ with detection at 254 nm by UV. Compounds **3a–d** and **4a** were previously reported.^{24–26}

4.1.1 General procedure for the synthesis of compounds 3a–d. These compounds were synthesized as per previously reported method.^{24,26} In a 350 mL round pressure vial 16–18 g urea was heated at 150–155 °C till it melted. To the liquid urea solution 0.1 eq. of **1a**, or **1b**, or **1c** or **1d** was added. The pressure vial was sealed and heated at 150–155 °C for 2 h, cooled to room temperature, followed by the addition of water (100 mL) after which the reaction mixture was heated at 100–105 °C for 1 h. After cooling to room temperature, the reaction mixture was diluted with ~80 mL EtOAc and washed with brine solution (50 mL × 4). The combined aqueous layers were washed with ~35 mL EtOAc, dried over MgSO₄ and the organic solvent was removed *in vacuo*. The solid obtained (compounds **2a–d**) was straightaway carried to the next step (yield 70–85%) without further purification. In a 250 mL RBF, 29.24 mmol of either **2a** or **2b** or **2c** or **2d** was suspended in 25 mL of anhydrous toluene and allowed to stir on an ice bath. To this, 5 eq. of POCl₃ was added in small aliquots followed by the slow addition of 5 eq. of DEA. The solution was kept on the ice bath for 10 min before moving to room temperature and allowed to stir for 1 h prior to refluxing at 105–110 °C for 14–16 h. Upon cooling to room temperature, the reaction mixture was added in small aliquots to a double-ice-water bath while stirring. The quenching solution was left stirring at room temperature for 5 h before vacuum filtering the yellowish-grey precipitate. The precipitate was stirred for 1 h in saturated NaHCO₃ solution and was filtered. This neutralization process was carried out 2–3 times until the bicarbonate solution maintains a neutral to slight basic pH. The final precipitate was dissolved in DCM and purified by a silica gel column chromatography using 100% DCM as the eluent to afford white to light grey solids **3a–d** (65–80%).

4.1.2 General procedure for the synthesis of compounds 4a–c, 5a–c, 6a and 7a. These compounds were synthesized as per previously reported method.^{27,28} To a 30 mL solution of ethanol in a 100 mL round-bottom flask on ice, ~21.46–25.13 mmol of either **3a** or **3b** or **3c** or **3d** was added followed by slow addition of 1.3 eq. (27.90–32.66 mmol) of the corresponding primary amine. Contents were stirred on an ice bath



while 2.0 eq. of diisopropyl-ethylamine (DIPEA, 42.92–50.25 mmol) was added in drop wise fashion. The solution was then heated at 80–85 °C under reflux for 3–4 h. The reaction contents were cooled to room temperature and precipitated residues were vacuum-filtered with EtOAc. The organic supernatant was concentrated *in vacuo* followed by two rounds of extraction using EtOAc and saturated brine solution (40–50 mL each respectively). The combined organic layers were dried over MgSO₄, evaporated *in vacuo* and purified (1–2 times) using silica gel column chromatography with 5 : 1 EtOAc : MeOH as the elution solvent to afford **4a–c**, **5a–c**, **6a** and **7a** as white to beige solids with yields ranging from 75–90%.

4.1.3 General procedure for the synthesis of compounds 8a–i, 9a–i, 10a–c, 11a–c, 12a–c, 13a–c, 14a and 15a. The target compounds were synthesized as per previously reported method.^{12,28} Briefly in a 50 mL pressure vial (PV), 0.25 g of 2,6-dichloro, 2,7-dichloro or 2,8-dichloro-*N*-substituted quinazolin-4-amine or 2-chloro-*N*-substituted pyrido[3,2-*d*]pyrimidine-2,4-diamine (~0.66–0.83 mmol) was combined with 2 eq. (~1.32–1.66 mmol) of primary amine (methyl-, ethyl-, *n*-propyl-, isopropyl- or cyclopropylamine) or dimethylamine which was dissolved in 5 mL of 1,4-dioxane followed by the addition of 3 eq. of DIPEA (~1.98–2.40 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 2 h. Upon completion and cooling to room temperature, the reaction mixture was diluted with ~40 mL of EtOAc and washed with brine solution (25 mL × 2). The combined aqueous layer was washed with ~25 mL of EtOAc. The combined EtOAc layers were dried over MgSO₄ before removing EtOAc *in vacuo* to yield a solid product that was purified by silica gel column chromatography using 5 : 1 EtOAc : MeOH as the eluent to afford pale yellow to brown solids (yield ~ 68–78%).

4.2 Experimental procedure for cholinesterase (*hAChE/hBuChE*) inhibition

Quinazoline and pyrido[3,2-*d*]pyrimidine derivatives (**8a–i**, **9a–i**, **10a–c**, **11a–c**, **12a–c**, **13a–c**, **14a** and **15a**) were evaluated for ChE inhibitory activity using Ellman's method.^{12,15,29} The test compounds compete with substrates acetylthiocholine iodide (ATChI) and *S*-butyrylthiocholine iodide (BuTChI) for either human AChE (Sigma-Aldrich, St. Louis, MO) or human BuChE (Sigma-Aldrich, St. Louis, MO), respectively. Known ChE inhibitors donepezil and rivastigmine were used as reference agents for comparison. Quinazoline and pyrido[3,2-*d*]pyrimidine derivatives were prepared in DMSO (maximum concentration used 1% v/v) and 10 μL each (0.001–25 μM final concentration range), was incubated for 5 minutes at room temperature with 160 μL of 1.5 mM DTNB, 50 μL 0.22 U mL⁻¹ AChE (in 50 mM Tris·HCl, pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 μL 0.12 U mL⁻¹ BuChE (in 50 mM Tris·HCl, pH 8.0, 0.1% w/v bovine serum albumin, BSA). After the incubation period, 30 μL of ATChI (15 mM, prepared in ultra pure water) or BuTChI (15 mM, prepared in ultra pure water) were added to 96-well plates. The ChE inhibition was measured at 412 nm wavelength using a microplate reader (BioTek Synergy H1 microplate reader) at various time intervals (*t* = 0, 1, 2, 3, 4

and 5 min). Appropriate controls, without the test compounds and ChE were included. The inhibitory concentration (IC₅₀ values) was calculated from the concentration-inhibition dose response curve on a logarithmic scale based on two independent experiments run in triplicates.

4.3 Experimental procedure for thioflavin T based Aβ aggregation kinetics

The anti-Aβ aggregation activity of test compounds (**8a–i**, **9a–i**, **10a–c**, **11a–c**, **12a–c**, **13a–c**, **14a** and **15a**), was evaluated using the ThT-based fluorescence assay.^{11,14} The Aβ40 and Aβ42 hexafluoro-2-propanol (HFIP) (rPeptide, Georgia, USA) stock solution was prepared by dissolving in 1% NH₄OH solution, to a 1 mg mL⁻¹ stock solution, followed by dilution to 50 μM in phosphate buffer (215 mM, pH 7.4). Stock solutions of test compounds were prepared in DMSO, diluted in phosphate buffer (pH 7.4), and were sonicated for 30 min. The final DMSO concentration per each well was 1% v/v or lower. The ThT fluorescent dye stock solution (15 μM) was prepared in 50 mM glycine buffer (pH 7.4). The aggregation kinetics assay was carried out using a Corning® 384-well flat, clear bottom black plates. Each well contains 44 μL of ThT, 20–35 μL of phosphate buffer (pH 7.4), 8 μL of test compounds in different concentrations (1, 5, 10 and 25 μM, final concentration) and 8 μL of either Aβ40 or Aβ42 (5 μM final concentration). The plate was incubated at 37 °C with a plate cover under shaking and fluorescence was measured every 5 min using a BioTek Synergy H1 microplate reader multimode plate reader (excitation = 440 nm and emission = 490 nm) over a period of 24 h. Appropriate control experiments that contain either Aβ40/42 and test compound alone were evaluated. The known Aβ aggregation inhibitors curcumin and resveratrol were used as reference agents. The IC₅₀ value (μM) was calculated using the equation 100% control - [(IFI-IFo)] where 100% control indicates no inhibitor, IFi and IFo are the fluorescence intensities in the presence and absence of ThT. The results were expressed as IC₅₀ values ± SD based on two separate experiments in triplicate measurements.

4.4 Experimental procedure for transmission electron microscopy (TEM)

In Costar 96-well, round-bottom plates were added 80 μL of 215 mM phosphate buffer, 20 μL of 10× test compound dilutions (250 μM – prepared in the same way as for the ThT assay) and 100 μL of Aβ40 or Aβ42 respectively (50 μM each). For the control wells, 2 μL of DMSO and 18 μL of phosphate buffer was added. Final Aβ: test compound ratio was 1 : 1 (25 μM : 25 μM). Plates were incubated on a Fisher plate incubator set to 37 °C and the contents were shaken at 730 cpm for 24 h. To prepare the TEM grids, ~20 μL droplet was added using a disposable Pasteur pipette over the formvar-coated copper grids (400 mesh). Grids were air-dried for about 3 h before adding two droplets (~40 μL, using a disposable Pasteur pipette) of ultra-pure water and using small pieces of filter paper to wash out precipitated buffer salts. After air-drying for ~15–20 min, the grids were negatively stained by adding a droplet (~20 μL, using



a disposable Pasteur pipette) of 2% phosphotungstic acid (PTA) and immediately after the grids were dried using small pieces of filter paper. Grids were further air-dried overnight. The scanning was carried out using a Philips CM 10 transmission electron microscope at 60 kV (Department of Biology, University of Waterloo) and micrographs were obtained using a 14-megapixel AMT camera.^{11,30}

4.5 Experimental procedure for molecular docking studies

The modeling experiments were carried out using Discovery Studio (DS), Structure-Based-Design version 4.0, software program from BIOVIA Inc, San Diego, USA. Quinazoline and pyrido[3,2-*d*]pyrimidine derivatives **8e**, **8h**, **9a**, **10b** and **12b** were built using the small molecules module in DS. For ChE docking studies, the X-ray coordinates of human AChE (pdb id:1B41) and BuChE (pdb id:1P0I) were obtained from protein data bank. The enzymes were prepared for docking using the macromolecules module in DS. The ligand binding site was defined by a 12 Å sphere for both AChE and BuChE.^{29,31} Docking simulation was carried out using the LibDock algorithm. During the docking simulation, CHARMM force field was used. The docked poses were evaluated using CDOCKER energy, CDOCKER interaction energy in kcal mol⁻¹ and by considering the type and number of polar and nonpolar contacts.³² The molecular docking of test compounds with the Aβ assembly was carried out by using the NMR solution structure (pdb id:2LMN). The Aβ dimer and Aβ fibril assemblies were built using the macromolecules module in DS.³² Ligand binding site was defined by selecting a 15 Å radius sphere for both Aβ dimer and fibril assembly. Molecular docking was performed using the receptor–ligand interactions module in DS. The LibDock algorithm was used to find the most appropriate binding modes of quinazoline/pyrido[3,2-*d*]pyrimidine derivatives (**8h** and **10b**) using CHARMM force field. The docked poses obtained were ranked based on the LibDock scores and the binding modes were analyzed by evaluating all the polar and nonpolar contacts between the ligands and Aβ-dimer and fibril regions.

4.6 Experimental procedure for iron [Fe(II)] chelation assay

Determined using the ferrozine (Sigma-Aldrich, USA) based competitive colorimetric assay.²³ Test compounds were initially dissolved in anhydrous methanol to 10 mM and diluted down to 105 μM using 100 mM tris buffer (pH 7.4). Then 95 μL of test compound solutions (final concentration of 50 μM in each well) were added to clear 96-well plates, followed by a 10 μL aliquot of iron sulphate (FeSO₄·7H₂O) stock solution (from 800 μM stock solution prepared in methanol). After a 5 minute incubation period at room temperature, 95 μL ferrozine solution (from 210 μM stock solution prepared in tris buffer) was added. After incubating at room temperature for 30 minutes the absorbance was measured at 562 nm and subtracted from compound blanks (95 μL of compound solutions + 105 μL of tris buffer) and compared to the ferrozine-only positive control (95 μL of tris buffer + 10 μL of iron sulphate + 95 μL of ferrozine). The results obtained were compared with known iron chelators; clioquinol (50 μM) and desferoxamine (50 μM). The results were reported

as average % iron-chelation ± SD in triplicate measurements based on two independent experiments.

Acknowledgements

The authors would like to thank the Faculty of Science, Office of Research, the School of Pharmacy at the University of Waterloo, Ontario Mental Health Foundation (graduate scholarship for TM), NSERC-USRA (for MM), NSERC-Discovery (RGPIN: 03830-2014), Canada Foundation for Innovation (CFI-JELF), Ontario Research Fund (ORF) and Early Researcher Award, Ministry of Research and Innovation, Government of Ontario, Canada (PR) for financial support of this research project.

References

- 1 A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini and M. Carlo, *J. Med. Chem.*, 2008, **51**, 347–372.
- 2 J. J. Lu, W. Pan, Y. J. Hu and Y. T. Wang, *PLoS One*, 2012, **7**, e40262.
- 3 R. E. Hughes, K. Nikolic and R. R. Ramsay, *Front. Neurosci.*, 2016, **10**, 177.
- 4 J. Birks, *Cochrane Database Syst. Rev.*, 2006, CD005593.
- 5 D. Lo and G. T. Grossberg, *Expert Rev. Neurother.*, 2011, **11**, 1359–1370.
- 6 P. T. Francos, A. M. Pamer, M. Snape and G. K. Wilcock, *J. Neurol., Neurosurg. Psychiatry*, 1999, **66**, 137–147.
- 7 M. Citron, *Nat. Rev. Drug Discovery*, 2010, **9**, 387–398.
- 8 M. Rosini, E. Simoni, A. Mielli, A. Minarini and C. J. Melchiorre, *J. Med. Chem.*, 2014, **57**, 2821–2831.
- 9 A. I. Bush, *J. Alzheimer's Dis.*, 2013, **33**, S277–S281.
- 10 T. Mohamed and P. P. N. Rao, *Curr. Med. Chem.*, 2011, **18**, 4299–4320.
- 11 T. Mohamed, A. Shakeri, G. Tin and P. P. N. Rao, *ACS Med. Chem. Lett.*, 2016, **7**, 502–507.
- 12 T. Mohamed and P. P. N. Rao, *Eur. J. Med. Chem.*, 2017, **126**, 823–843.
- 13 S. Darvesh, D. A. Hopkins and C. Geula, *Nat. Rev. Neurosci.*, 2003, **4**, 131–138.
- 14 H. Levine, *Protein Sci.*, 1993, **2**, 404–410.
- 15 G. L. Ellman, K. D. Courtney, V. Andres Jr and R. M. Feather-Stone, *Biochem. Pharmacol.*, 1961, **7**, 88–95.
- 16 A. T. Petkova, W. M. Yau and R. Tycko, *Biochemistry*, 2006, **45**, 498–512.
- 17 G. Kryger, M. Harel, K. Giles, L. Toker, B. Velan, A. Lazar, C. Kronman, D. Barak, N. Ariel, A. Shafferman, I. Silman and J. L. Sussman, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2000, **56**, 1385–1394.
- 18 Y. Nicolet, O. Lockridge, P. Masson, J. C. Fontecilla-Camps and F. Nachon, *J. Biol. Chem.*, 2003, **278**, 41141–41147.
- 19 J. S. Choi, J. J. Braymer, R. P. Nanga, A. Ramamoorthy and M. H. Lim, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 21990–21995.
- 20 M. G. Savelieff, A. S. DeToma, J. S. Derrick and M. H. Lim, *Acc. Chem. Res.*, 2014, **47**, 2475–2482.



- 21 M. P. Horowitz and J. T. Greenamyre, *J. Alzheimer's Dis.*, 2010, **20**, S551–S568.
- 22 L. X. Yang, K. X. Huang, H. B. Li, J. X. Gong, F. Wang, Y. B. Feng, Q. Tao, Y. H. Wu, X. K. Li, X. M. Wu, S. Zeng, S. Spencer, Y. Zhao and J. Qu, *J. Med. Chem.*, 2009, **52**, 7732–7752.
- 23 M. Karamac, *Int. J. Mol. Sci.*, 2009, **10**, 5485–5497.
- 24 R. A. Smits, I. J. de Esch, O. P. Zuiderveld, J. Broeker, K. Sansuk, E. Guaita, M. Adami, E. Haaksma and R. Leurs, *J. Med. Chem.*, 2008, **51**, 7855–7865.
- 25 Z. Li, D. Wu and W. Zhong, *Heterocycles*, 2012, **85**, 1417–1426.
- 26 A. Tikad, S. Routier, M. Akssira, J. M. Leger, C. Jarry and G. Guillaumet, *Synlett*, 2006, **12**, 1938–1942.
- 27 T. Mohamed, J. C. Yeung, M. S. Vasefi, M. A. Beazely and P. P. N. Rao, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 4707–4712.
- 28 T. Mohamed, A. Assoud and P. P. N. Rao, *Acta Crystallogr., Sect. E: Struct. Rep. Online*, 2014, **70**, o554.
- 29 T. Mohamed, X. Zhao, L. K. Habib, J. Yang and P. P. N. Rao, *Bioorg. Med. Chem.*, 2011, **19**, 2269–2281.
- 30 V. L. Anderson, T. F. Ramlal, C. C. Rospigliosi, W. W. Webb and D. Eliezer, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 18850–18855.
- 31 G. Tin, T. Mohamed, N. Gondora, M. B. Beazely and P. P. N. Rao, *MedChemComm*, 2015, **6**, 1907–2044.
- 32 P. P. N. Rao, T. Mohamed, K. Teckwani and G. Tin, *Chem. Biol. Drug Des.*, 2015, **86**, 813–820.

